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Abstract: Investigating the infectivity of body fluid can be useful for preventative measures in the community and ensuring safety in the operating rooms and 
on the laboratory practices. We performed a literature search of clinical trials, cohorts, and case series using PubMed/MEDLINE, Google Scholar, and Cochrane 
library, and downloadable database of CDC. We excluded case reports and searched all-language articles for review and repeated until the final drafting. The search 
protocol was registered in the PROSPERO database. Thirty studies with urinary sampling for viral shedding were included. A total number of 1,271 patients were 
enrolled initially, among which 569 patients had undergone urinary testing. Nine studies observed urinary viral shedding in urine from 41 patients. The total inci-
dence of urinary SARS-CoV-2 shedding was 8%, compared to 21.3% and 39.5 % for blood and stool, respectively. The summarized risk ratio (RR) estimates for 
urine positive rates compared to the pharyngeal rate was 0.08. The pertaining RR urine compared to blood and stool positive rates were 0.20 and 0.33, respectively. 
Our review concludes that not only the SARS-CoV-2 can be excreted in the urine in eight percent of patients but also its incidence may have associations with 
the severity of the systemic disease, ICU admission, and fatality rates. Moreover, the findings in our review suggest that a larger population size may reveal more 
positive urinary cases possibly by minimizing biases.
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Introduction
Urinary viral shedding can be important from the 
aspects of diagnosis, vertical and horizontal transmis-
sion of infection (1). Viral shedding has been proven 
for some other contagious viruses including the Ebola 
virus, Zika virus, and hepatitis-B virus (2, 3).
Up to date, SARS-CoV-2 has spread to 213 countries 
and territories and infected over 28,000,000 patients 
around the globe with around 1,000,000 death toll 
(4). Before Coronavirus disease-2019 (COVID-19), 
the latest coronavirus outbreaks were the severe acute 
respiratory syndrome coronavirus-1 (SARS-CoV-1) 
and Middle Eastern respiratory syndrome coronavi-
rus (MERS-CoV) outbreaks. For SARS-COV-1, the 
urinary positivity rates were reported to be up to 42% 
(5).  SARS-CoV-2 structural features are similar to both 
SARS-CoV-1 and MERS-CoV which all belong to the 
family Coronaviridae (6).
The presence of SARS-CoV-2 has been shown 
in urine (7-12). Angiotensin-converting enzyme-II 
(ACE2) has been known as the cellular entry receptor of 
SARS‐ CoV‐2 (13, 14). The cells with ACE-II receptors 
such as epithelia of lung, kidney, and bladder may act as 
targets to SARS-CoV-2 (9, 15, 16). Although there are 
discrepancies in the reported results of the studies over 
the SARS CoV-2 urinary shedding, since the viral dyna-
mics are yet to be fully determined, it has been recom-
mended that the urethral or ureteral instrumentation and 
handling should be carried out cautiously (17).
Determining whether the virus is detectable throu-
ghout the disease is critical to control transmission. 
Considering the stability of SARS-CoV-2 for up to 72 
hours (18), performing urological surgeries, or collec-
ting infected urinary samples may put urologists and 
health care workers at risk (19). The Ebola virus epi-
demic (2014 to 2015) was an awakening alarm for the 
health care community regarding the lack of biosafety 
in the handling of samples containing suspected special 
pathogens (20). his is true, particularly for the novel 
pathogens in fluid samples (21), as the recommenda-
tions are often fluid (21). Learning about the infectivity 
also can alter preventative measures in the operating 
room and the settings needed for safety on laboratory 
practices (22).
Furthermore, the probability of transmission by 
pets (23, 24), leaves urine with a large potential to be a 
source of disease spread (25, 26). Although no data are 
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available to confirm or exclude the possibility of such 
transmission, CDC advises restricting contact with pets 
and other animals while one has COVID-19 (27).
By this review, we systematically investigated the 
findings on the urinary SARS-Cov-2 to points out the 
important methodological considerations needed to be 
considered in future studies.
Materials and Methods
The protocol for this systematic review was registered 
with the International Prospective Register of Systema-
tic Reviews (CRD42020187294). The review follows 
the PRISMA (Preferred Reporting Items for Systematic 
Reviews and Meta-analysis) statement (28).
Literature search strategies
A systematic search of the literature was performed 
in PubMed/MEDLINE, Google Scholar, Cochrane li-
brary, and COVID-19 research articles downloadable 
database of CDC (Centers for Disease Control and Pre-
vention). The comprehensive literature was performed 
in June 2020. No language restrictions were applied. 
Articles published in 2019 and 2020 were included. 
Searches were repeated until the final drafting of the 
manuscript, to capture emerging evidence from the 
ongoing studies. The searches included medical sub-
ject headings (MeSH) and keywords for SARS-CoV-2, 
COVID, Corona, together with shedding, persistence, 
urine, urinary, specimen, viral load, or RNA body fluids. 
Searches were designed to be broad and comprehen-
sive initially, using the following keywords and MeSH 
terms: (“specimen” or “urine” or “urinary”) and  (“co-
rona” or “coronavirus” or “COVID” or “COVID-19” 
or “COVID-2019” or “SARS” or “SARS-CoV” or 
“SARS-CoV-2”).
Eligibility criteria and study selection
Study selection was based on predefined eligibility 
criteria within a CoCoPop (Condition, Context, Popu-
lation) and a PIRD (Population, Index Test, Reference 
test, Diagnosis of Interest) format (Table 1) (29). Ad-
ditional exclusion criteria were applied at the full-text 
stage. After finalizing the selection of studies on the 
urinary SARS-CoV-2, information on viral existence in 
stool and blood specimens were explored in the selected 
studies (Figure 1).
All studies required a minimum of 2 patients were 
included. All potential studies were independently 
screened by two investigators. In the case disagreement, 
it resolved either through discussion or the involvement 
of a third researcher according to Delphi consensus cri-
teria. Clinical trials, retrospective, prospective observa-
tional, case series, and cross-sectional studies were in-
cluded as well as supplementary or non-peer-reviewed 
reports, correspondence, research letters, and preprints. 
Review articles, case reports, or non-relevant articles 
were excluded from the pool. Following reviewing and 
extraction of data, references of each manuscript ‎were 
Inclusion Exclusion
Population  Any age with a confirmed COVID-19 on the admission or later • Animal studies 
Interventions  Real-time RT-PCR 
• Limited to non-RT-PCR
• Innovative methods or uncommon 
genes incorporated to the test 
Comparisons  Stool and serum specimens  
Outcomes   Existence of shedding of viral RNA
Type of Study 
Any study more equal/more than 2 cases with 
original data (including  editorials, letters, comments, 
abstracts, summaries, Case reports )
• Case Reports
• Review articles
• Publications with no original data 
(e.g. comments, reviews) 
• Non-English publications 
Timing and Setting • 2019 and 2020• All settings 
Table 1. List of inclusion/exclusion criteria.
Figure 1. Preferred reporting items for systematic reviews and 
meta-analyses (PRISMA) flow diagram shows the study selec-
tion process. Adapted from Moher et al. (doi.org/10.1371/journal.
pmed.1000097) ©2009, under terms of Creative Commons Attri-
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8%. This was 21.3% and 39.5 % for blood and stool 
respectively.
Study characteristics and urinary testing population
Characteristics of the included studies, comparison 
among positive and negative studies are detailed in 
Tables 2, 3, and Figure 2.
I. Primary Study Population: A total number of 1,271 
COVID-19 patients were enrolled initially in the stu-
dies. The confirmatory testing was positive pharyngeal 
swabs, except two studies that included four patients 
with initially negative pharyngeal but positive stool re-
sults (13, 40). Essentially, all studies included patients 
with a median age between 40s and 60s (ranged from 6 
months to 92 years). 
II. Ultimate Urinary Tested Population: Of 746 pa-
tients, 439 had undergone urinary testing. In three stu-
dies, the number of urinary tests patients were not avai-
lable, instead, the total number of laboratory samples 
(119 samples in total) was reported (Diagram 2).
III. Stool/rectal Swab and Blood Sampling: Of 30 stu-
dies with urinary sampling for viral shedding, 21 stu-
dies performed fecal/rectal swab testing and 22 studies 
accomplished blood viral testing.
Laboratory methods to identify SARS CoV-19 in the 
literature
Within the literature examined, the most commonly 
searched for relevant missing manuscripts.
Data extraction
We created standardized forms for data extraction 
and the pilot tested the forms before the process of data 
extraction. We completed the data abstraction process 
using created forms to record study characteristics, cli-
nical data, and laboratory data including study year and 
design, country of study origin, total initial ‎population 
size, test type for ‎disease diagnosis, test type for samples 
‎‎‎(urine/stool/rectal swab/blood)‎, patients age (including 
mean and range), number of positive and total patients 
and/or (wherever applicable) number of positive and 
total specimens collected for each test category, disease 
severity, ICU admission, and fatality rate. More details 
for study items are shown in Table 2. 
Risk of bias assessment and strength of body of evi-
dence
Two investigators assessed the risk of bias for indivi-
dual studies independently using JBI's (Joanna Briggs) 
critical appraisal tools for prevalence study and dia-
gnostic test accuracy studies to assess the trustworthi-
ness, and results of the studies (30-32).
Statistical analysis
Forest plots were used to assess risk ratio (RR) and 
summarized them to describe RR of viral shedding rates 
in the urine and control groups (i.e., nasopharynx, stool, 
blood). Primary, secondary, and tertiary meta-analysis 
was conducted among all studies that reported urine 
and nasopharynx positive rates, urine, and stool posi-
tive rates, urine, and serum positive rates as an outcome, 
respectively. The heterogeneity across studies was eva-
luated using p-values, and Q and I2 statistics. Random 
effect and fixed effect meta-analysis were used when the 
heterogeneity was greater and lower than 50%, respec-
tively. P-values lower than 0.05 were considered statis-
tically significant. All analyses were carried out using 
Stata version 14.
Results
A total of 30 studies met the inclusion criteria and 
were included in the review (8-13, 17, 35-49). The ove-
rall prevalence of urinary SARS-CoV-2 shedding was 
Studies with positive findings Studies with completely negative urine
Number of studies  9 studies 21 studies








Initial number of enrolled patients 715 556
Final number enrolled for urinary testing 372 197 
Stool positivity 42% 42%
Blood positivity 22% 21%
Severity of the disease 50.6% 21%
ICU 18% 28.3%
Table 2. Comparison among studies with and without positive results on the urinary viral rRT-PCR.
Figure 2. Flow chart diagram comparing studies in terms of urine, 
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Study Country Initial population
Age
(mean/ median)
Patients¶  with (+) urine 
among tested ones
Urine samples¶  
tested 
Zhang N  (33) China/Beijing 23 48 * 2/23 2/56
Ling Y (34) China/Shanghai 66 44 4/58 
Wang L (35) China/Wuhan 116 54 5/53
Zheng S (10) China 96 55 1/67
Tan W (36) China 67 49 12/64
Mondanizadeh M (37) Iran 50 46 0/50
Peng L (38) China 9 38.9 1/9
Kujawski SA (39) USA/CDC 12 53  0/10 
Ghinai I (40) USA/Illinois 2 NA 0/2 0/12
Young BE (41) Singapore 18 47 0/10
Wölfel R (42) Germany/Munich 9 NA 0/9 0/27
Lescure XF (43) France/Paris 5 48 0/5
Yu F (44) China/Beijing 76 40* NA 0/14
To KKW (45) China/Hong Kong 23 62* 0/23
Chan JFW (16) China/Hong Kong 5 55.4 0/5
Wang W (46) China/Beijing 205 44 NA 0/72
Pan Y(X) (47) China/Beijing 2 NA 0/2
Lo IL (48) China/Macau SAR 10 54 0/10 0/49
Chan JFW (49) China/Hong Kong 15 63 NA 0/33
Chen Y (50) China/Wuhan 42 51 0/10
Fang Z (51) China/Xiangtan 32 41 0/23
Mumm JN (52) Germany/Munich 7 62 0/6
Diao B (53) China/Wuhan 259 NA 14/19
Qiu L (54) China/Beijing 10 52 to 80 0/10
Xie C (55) China/Chengdu 19 33 0/9
Kim JY (56) Korea/ Seoul 2 45 0/2
Couturier A (57) France/Paris 2 53 0/2
Jeong HW (58) Korea/Cheongju 5 63 5/5
Liu P (59) China/Shanghai 9 NA 0/9
Kim JM (60) Korea/Cheongju 74 43 2/74 2/274
* median; ¶ the provided numbers are positive cases/specimens out of available total ones
Table 3. Demographic information of studies and urinary viral results.
Study Case-Fatality (death/total cases) Severe Pneumonia (/total cases) ICU /ARDS (/total cases)
Zhang N 0 2/23
Ling Y 0
Wang L 7/116 46/116 11/116
Zheng S 0 74/96 30/96
Tan W 0 29/67 9/67
Mondanizadeh M
Peng L
Kujawski SA 0 0 1/12
Ghinai I 0 0 0
Young BE 0 5/18 2/18
Wölfel R 0 0 0
Lescure XF 1/5 3/5 3/5
Yu F 17/76
To KKW 2/23 10/23 5/23
Chan JFW 0 3/6
Wang W 39/205
Pan Y(X) 1/2
Lo IL 0 4/10 0
Chan JFW
Chen Y 0 11/42










Table 4. Clinical characteristics of patients in studies.
*Blank spaces= no data was provided.
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used assays for detection of SARS- CoV-2 in different 
samples such as urine, stool, blood, and pharyngeal sw-
abs were RNA extraction followed by semi-quantitative 
and quantitative real-time reverse transcriptase-polyme-
rase chain reaction (real-time RT-PCR, or rRT-PCR). In 
some studies, serological and molecular methods such 
as enzyme-linked immunosorbent assay (ELISA), par-
tial and whole-genome sequencing were used for more 
verification. Several specific primers pairs were used to 
amplification of gene regions including RdRp/helicase, 
spike, and nucleocapsid genes of SARS-CoV-2. Such 
data were not available for all papers.
Severity, ICU admission, fatality rate, and patient 
enrolling 
The COVID-19 severity and ICU admission rates 
are detailed in Table 4.
•  20.1% of the total initial population were admitted 
into the ICU, as reported in 13 studies. 
• 33.0% of the total initial population had severe respi-
ratory disease because of SARS-CoV-2, as reported in 
16 studies.
• There was no information about the severity or ICU 
admission in the rest of the studies. Four studies that 
included the cases terminated by death reported a total 
fatality rate of 7.6% (11/144). The other 11 studies only 
enrolled survived cases. Related information was not 
provided in 15 studies.
Shedding in urine and other specimens
The results are shown in Table 5 and Figure 2.
I. Urinary results: Of 30 studies, urinary viral shedding 
was observed in nine studies.
II. Stool or rectal swab results: 19 of 23 studies found 
positivity in the stool samples.
III. Blood testing results: 14 out of 25 studies reported 
positive results.
Meta-analysis
Meta-analysis was performed across the urinary stu-
dies. The summarized RR of 30 retrospective studies 
that reported urine compared to nasopharynx positive 
rates, was 0.08 (95% confidence intervals (CI); 0.05-
0.16). The pertaining RR urine compared to blood and 
stool positive rates were 0.20 (95% CI; 0.14-0.29) and 
0.33 (95% CI; 0.15-0.72) respectively. The forest plots 
of the meta-analysis are shown in Figures 3-5. There 
was no significant heterogeneity across all studies that 
included in the all meta-analysis, therefore fixed-effect 
analyses have been used.
Discussion
According to our three meta-analyses, stool and 
blood tests are associated with a significantly higher 
positive rate than urine (Figures 1-3). These results 
indicated that when the naso-/oro-pharyngeal SARS-
CoV-2 test is negative, stool, and/or blood tests are more 
helpful for virus diagnosis than urine. Nevertheless, dif-
ferent factors such as the nature of viruses, missing data, 
design flaws, or methodological limitations might have 
contributed to these findings. The importance of urinary 
viral infection should not be ignored in terms of pro-
tective measures.  We reviewed some important factors 
STUDY Stool(+) Patients¶ Stool (+)Specimens¶ Blood(+) Patients¶ Blood(+) Specimens¶
Zhang N 10/12 33/51 0/23 0/56
Ling Y 11/66 - 0/14 -
Wang L - - - -
Zheng S 55/93 - 39/95 -
Tan W 45/62 - 9/63 -
Mondanizadeh M 2/50 - 3/50 -
Peng L 2/9 - 2/9 -
Kujawski SA 7/10 - 1/12 -
Ghinai I 1/2 4/11 0/2 0/14
Young BE 4/8 - 1/12 -
Wölfel R 0/4 0/13 0/9 0/31
Lescure XF 2/5 - 1/5 -
Yu F - - NA 0/4
To KKW 4/23 - 5/23 -
Chan JFW 0/2 - 2/6 -
Wang W NA 44/153 NA 3/307
Pan Y(X) 0/2 - - -
Lo IL 10/10 46/79 - -
Chan JFW NA 7/33 NA 10/87
Chen Y 28/42 - - -
Fang Z - - 23/32 -
Mumm JN - - 2/4 -
Diao B - - - -
Qiu L - - 0/10 -
Xie C 8/9 - 0/9 -
Kim JY 0/2 - 1/2 -
Couturier A - 0/1 -
Jeong HW 5/5 - 5/5 -
Liu P 8/9 - 0/9 -
Kim JM 8/74 13/129 6/74 9/323
Table 5. Positive real-time RT-PCR (rRT-PCR) findings of other specimens in the studies.
¶ the provided numbers are positive cases/specimens among tested cases
*rRT-PCR=Real-time Reverse Transcription Polymerase Chain reaction  
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that can influence the results.
COVID severity can be evidenced by the needs for 
mechanical ventilation, ICU care, as well as higher fa-
tality. Viremia and sepsis are usually representative of 
more severe forms of diseases and a potential source for 
viral urinary shedding. 
In SARS-CoV-1, viremia was reported to be asso-
ciated with disease severity (61). Similarly, severely ill 
patients in the setting of SARS-CoV-2 disease may have 
augmented and prolonged the existence of the virus in 
blood and other body fluids (10).  Furthermore, urinary 
viral positivity was found in severe cases in a study (7). 
SARS-CoV-2 viremia also may occur in patients with 
underlying comorbidities (62). Moreover, the duration 
of viral RNA excretion in respiratory and stool speci-
mens may be longer in the cases treated with glucocor-
ticoid, an immunosuppressive medication (8, 10). Ac-
cordingly, we emphasize the importance of inclusion of 
severely ill patients and ones with an underlying disease 
in the shedding studies.
In a study with a comparatively higher rate of uri-
nary shedding (9.5%), a significantly higher proportion 
of the population had severe disease (40%) along with 
a case fatality of 6% (9). In another study, the duration 
of the existence of the virus in the blood of ICU patients 
was longer. The authors suggested its relationship with 
blood viral load and disease severity. Viruses were not 
found in the urine samples. Although their classification 
based on ICU admission was informative, the study did 
not have any information on whether the cases who 
ended in death _which might bear a higher urinary posi-
tive rate_ had not been excluded from the study (63). 
Similarly, some other studies with totally negative uri-
nary results were limited to the populations with mild or 
moderate severity with null fatality (64, 65).
According to figure 2, the incidence risk of viral 
shedding in stool or blood was similar for both groups 
of studies with and without positive results. While 
trying to justify why a study has positive urinary results 
but another study does not, the mentioned finding might 
not be in favor of the hypothesis that it could have ari-
sen from systematic flaws in or in inclusion or exclusion 
criteria, sampling, or handling methods.
Nevertheless, a lack of concordance between the se-
verity of disease and ICU admission rates in two groups 
in table 2 indicates heterogeneity of study populations 
among the studies.
As a result, since the difference in the severity of 
COVID-19 may contribute to the urinary negative re-
sults, we suggest to consider it while planning the study.
Determining when the virus is detectable in the 
urine, is not simple. Different phases of the disease may 
lead to considerable differences in viral loads and peak 
concentrations and can be another factor responsible 
for different urinary findings. Toward the end of the 
period of the COVID disease, the virus is shown to be 
only intermittently detectable in pharyngeal swabs (41). 
Since the pharyngeal samples have much higher posi-
tive rates, finding a virus in the other fluid types could 
be more challenging.
As reported in SARS-CoV-1 studies, the urinary po-
sitivity rate was up to 42% at the end of the second week 
(5) with a peak occurring at weeks 3–4 and even shed-
ding in the convalescent phase (66, 67). Similarly, for 
SARS-CoV-2, positive urine samples were detected at 
the latest available detection point (16 or 21 days after 
illness onset) (7).
 Another study with a urinary positivity rate of 6.9% 
for viral RNA, revealed urine could stay positive after 
the throat swabs turned negative (8).
Although regular serial sampling was performed 
for pharyngeal specimens in some of the studies in our 
review, that was not the case for urine. Since repeat uri-
nary testing is warranted especially in clinically suspec-
ted cases with an initially negative urinary result, we 
would emphasize the importance of systematic serial 
sample monitoring, throughout the disease phases, with 
an increased number of tested samples.
Failure to find urinary viruses in many studies may 
be explained by their undersized study population. This 
may contribute to the positivity of urinary results found 
in studies done in China which were larger in popula-
Figure 3. Forest plot, Relative risk of urine shedding of SARS-
CoV-2 compared to pharyngeal specimens in the confirmed CO-
VID-19 patients.
Figure 4. Forest plot, Relative risk (RR) of urine shedding of 
SARS-CoV-2 compared to the stool in the confirmed COVID-19 
patients.
Figure 5. Forest plot, Relative risk of urine shedding of SARS-
CoV-2 compared to blood in the confirmed COVID-19 patients.
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tion. Our review demonstrated that a considerable num-
ber of studies with a larger population were able to find 
positive urinary results (10, 34, 36, 53, 60, 68).
Moreover, there was a considerable difference in 
number between the population initially enrolled and 
finally tested for urine. Exclusions were not explained, 
as in some studies it was found to be more than half of 
the initial population. Except for one study, all the men-
tioned studies were accompanied by no positive urinary 
results (9, 49, 53, 69).
Some studies with negative urinary results in this 
review had no stool positive findings (62, 65, 70), even 
though stool has been proven to have a high possibility 
of viral shedding (48.1%) (71). This co-negativity may 
also be explained by the errors in handling and labora-
tory technics. 
Although real-time RT-PCR is considered as the gold 
standard for the diagnosis of COVID-19 (72), some 
factors such as the RNA quality, operator variability, 
or processing methods can affect the test results (73-
75). Also, this technique does not distinguish between 
RNA residues and viable active viruses (76). As SARS-
CoV-2 shares a high nucleotide identity with SARS-
CoV-1 (82%) (77), using nonspecific real-time RT-PCR 
(e.g. SYBR Green method) may cause false-positive 
results. Some studies reviewed herein, lack informa-
tion concerning the real-time RT-PCR type, primer, and 
probe sequences, candidate genes for virus detection, 
presence or absence of positive control, and the cycling 
parameters for PCR assay. 
Real-time RT-PCR Ct (cycle threshold) values may 
also differ because of specimen collection or handling. 
The presence of several enzymes such as protease, 
RNase, or bacteria and the absence of proteins that sta-
bilize RNA and virus in the urine may explain the quick 
degradation of viral RNA (78, 79). Technical impro-
vement in the sampling to prevent degradation of the 
urinary viral RNA (such as immediate addition of lysis 
buffer to the fresh urine) may help to increase the dia-
gnostic sensitivity and diminish false negative (78, 80). 
Further studies are needed to assess the efficacy of these 
methods in SARS-CoV-2.
Another source of false-positive urinary results can 
be passive contamination of urine samples with stool or 
other sources that can occur in severely ill or in the pres-
ence of diarrhea. The presence of different genotypes in 
urine or the comparatively higher RNA concentrations 
in urine would indicate active replication in the urine 
rather than contamination and spillage.
As can be noticed so far, this review encountered 
several limitations that resulted from a lack of high-qua-
lity evidence. We just mentioned the most important to-
pics that help in building researches with a deeper focus 
on the design and methodologic quality in the future and 
help assess the viral shedding in urine and other speci-
mens more efficiently.
Based on review of the present literature, shedding 
of SARS-CoV-2 occurs in around 10 percent of popu-
lation and it may have an association with the severity 
of systemic disease, need to admission in ICU and fata-
lity. Investigating relationship between urine results and 
other factors is hardly possible without avoiding inap-
propriate exclusions.  Furthermore, our review suggests 
that a larger population size may reveal more positive 
urinary cases. Moreover, using standardized laborato-
ry quantitative control in real-time RT-PCR as well as 
repeat urinary testing would be warranted especially in 
patients with initially negative urinary results. 
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